Cargando…

The role of abemaciclib in treatment of advanced breast cancer

Until recently, the mainstay of treatment in the majority of hormone receptor (HR)-positive, human epidermal growth factor 2 receptor (HER2)-negative advanced breast cancer (ABC) has consisted of single-agent endocrine therapy (ET). However, as understanding of endocrine resistance has grown, newer...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCartney, Amelia, Moretti, Erica, Sanna, Giuseppina, Pestrin, Marta, Risi, Emanuela, Malorni, Luca, Biganzoli, Laura, Di Leo, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985604/ https://www.ncbi.nlm.nih.gov/pubmed/29899762 http://dx.doi.org/10.1177/1758835918776925

Ejemplares similares

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
por: Vignoli, Alessia, et al.
Publicado: (2021)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
por: Galardi, Francesca, et al.
Publicado: (2021)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification
por: McCartney, Amelia, et al.
Publicado: (2019)

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
por: Turner, Natalie, et al.
Publicado: (2014)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2022)

Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients
por: Risi, Emanuela, et al.
Publicado: (2022)

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
por: McCartney, Amelia, et al.
Publicado: (2020)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
por: Biganzoli, Laura, et al.
Publicado: (2020)

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
por: Di Leo, Angelo, et al.
Publicado: (2018)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
por: Galardi, Francesca, et al.
Publicado: (2020)

Abemaciclib for breast cancer
Publicado: (2020)

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
por: Johnston, Stephen, et al.
Publicado: (2019)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
por: Oakman, Catherine, et al.
Publicado: (2010)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Significance of Micrometastases: Circulating Tumor Cells and Disseminated Tumor Cells in Early Breast Cancer
por: Oakman, Catherine, et al.
Publicado: (2010)

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting
por: Di Donato, Samantha, et al.
Publicado: (2021)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer
por: Oakman, Catherine, et al.
Publicado: (2009)

The best treatment for older patients with breast cancer
por: Turner, Natalie, et al.
Publicado: (2013)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
por: Johnston, Stephen, et al.
Publicado: (2021)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer
por: Hao, Chunfang, et al.
Publicado: (2022)

Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer
por: Kurtyka, David J., et al.
Publicado: (2021)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
por: Lim, Elgene, et al.
Publicado: (2022)

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers
por: Zhang, Jian, et al.
Publicado: (2021)

Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib
por: Smyth, Emily Nash, et al.
Publicado: (2022)

A multifactorial ‘Consensus Signature’ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer
por: Turner, Natalie, et al.
Publicado: (2015)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

A Likely Case of Abemaciclib-Induced Hyperpigmentation in a Patient With Metastatic Breast Cancer
por: Salusti-Simpson, Michela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q91o0754286cq3du38f3257ld4